Calcium signaling and cell fate: How can Ca2+ signals contribute to wrong decisions for chronic lymphocytic leukemic B lymphocyte outcome?

International Journal of Developmental Biology

Volumn 59, Issue 7-9, 2015, Pages 379-389

  Debant, Marjolaine ^a,b,c   Hemon, Patrice ^a,b,c   Brigaudeau, Christophe ^a,c   Renaudineau, Yves ^b,c   Mignen, Olivier ^a,c  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b Universite de Brest   (France)

^c (IC CGO)   (France)

Author keywords

Calcium; CD5; Cell fate; Chronic lymphocytic leukaemia

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD79 ANTIGEN; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; PROTEIN BCL 2; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE PHOSPHATASE SHP 1; CALCIUM;

ARTICLE; B LYMPHOCYTE; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DOWN REGULATION; ENDOPLASMIC RETICULUM; HUMAN; NEGATIVE FEEDBACK; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; HOMEOSTASIS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; B-LYMPHOCYTES; CALCIUM; CALCIUM SIGNALING; HOMEOSTASIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84947907063     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.150204om     Document Type: Article

References (105)

1. AKL H, VERVLOESSEM T, KIVILUOTO S, BITTREMIEUX M, PARYS JB, DE SMEDT H and BULTYNCK G (2014). A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Biochim Biophys Acta 1843: 2240-2252.
2. BABA Y and KUROSAKI T (2009). Physiological function and molecular basis of STIM1-mediated calcium entry in immune cells. Immunol Rev 231: 174-188.
3. 2+ signaling on B cell function. Trends Immunol 32: 589-594.
4. 2+ increase and its sensor molecules, STIM1 and STIM2. Mol Immunol 62: 339-343.
5. BABAY A, NISHIDAK S, FUJII Y, HIRANO T, HIKIDA M and KUROSAKI T (2008). Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses. Nat Immunol 9: 81-88.
6. BENSCHOP RJ, BRANDL E, CHAN AC and CAMBIER JC (2001). Unique signaling properties of B cell antigen receptor in mature and immature B cells: implications for tolerance and activation. J Immunol 167: 4172-4179.
7. BERGMEIER W, WEIDINGER C, ZEE I and FESKE S (2013). Emerging roles of store-operated Ca(2)(+) entry through STIM and ORAI proteins in immunity, hemostasis and cancer. Channels (Austin) 7: 379-391.
8. BERLAND R and WORTIS HH (2002). Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20: 253-300.
9. BERNAL A, PASTORE RD, ASGARY Z, KELLER SA, CESARMAN E, LIOU HC and SCHATTNER EJ (2001). Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98: 3050-3057.
10. BERRIDGE MJ (2012). Calcium signalling remodelling and disease. Biochem Soc Trans 40: 297-309.
11. BERRIDGE MJ, BOOTMAN MD and RODERICK HL (2003). Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4: 517-529.
12. BIKAH G, CAREY J, CIALLELLA JR, TARAKHOVSKY A and BONDADA S (1996). CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274: 1906-1909.
13. BUGGINS AG and PEPPER CJ (2010). The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 34: 837-842.
14. Burger JA and Chiorazzi N (2013). B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34: 592-601.
15. CAMBIER JC, GAULD SB, MERRELL KT and VILEN BJ (2007). B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol 7: 633-643.
16. CARSETTI L, LAURENTI L, GOBESSI S, LONGO PG, LEONE G and EFREMOV DG (2009). Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation. Cell Signal 21: 1187-1194.
17. CHEN L, HUYNH L, APGAR J, TANG L, RASSENTI L, WEISS A and KIPPS TJ (2008). ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 111: 2685-2692.
18. CHEN L, WIDHOPF G, HUYNH L, RASSENTI L, RAI KR, WEISS A and KIPPS TJ (2002). Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100: 4609-4614.
19. CHIORAZZI N and EFREMOV DG (2013). Chronic lymphocytic leukemia: a tale of one or two signals? Cell Res 23: 182-185.
20. COOKE MP, HEATH AW, SHOKAT KM, ZENG Y, FINKELMAN FD, LINSLEY PS, HOWARD M and GOODNOW CC (1994). Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med 179: 425-438.
21. DAMLE RN, WASIL T, FAIS F, GHIOTTO F, VALETTO A, ALLEN SL, BUCHBINDER A, BUDMAN D, DITTMAR K, KOLITZ J, LICHTMAN SM, SCHULMAN P, RAI KR, FERRARINI M and CHIORAZZI N (1999). Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847.
22. DEGLESNE PA, CHEVALLIER N, Letestu R, Baran-Marszak F, BEITAR T, SALANOUBAT C, SANHES L, NATAF J, ROGER C, Varin-Blank N and Ajchenbaum-Cymbalista F (2006). Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res 66: 7158-7166.
23. DISTELHORST CW and BOOTMAN MD (2011). Bcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: role in Ca(2+) signaling and disease. Cell Calcium 50: 234-241.
24. DUHREN-VON MINDEN M, UBELHART R, SCHNEIDER D, WOSSNING T, BACH MP, BUCHNER M, HOFMANN D, SUROVA E, FOLLO M, KOHLER F, WARDEMANN H, ZIRLIK K, VEELKEN H and JUMAA H (2012). Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489: 309-312.
25. EFREMOV DG, GOBESSI S and LONGO PG (2007). Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Auto-immun Rev 7: 102-108.
26. ENGELKE M, ENGELS N, DITTMANN K, STORK B and WIENANDS J (2007). Ca(2+) signaling in antigen receptor-activated B lymphocytes. Immunol Rev 218: 235-246.
27. FESKE S (2007). Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 7: 690-702.
28. FESKE S (2010). CRAC channelopathies. Pflugers Arch 460: 417-435.
29. FESKE S (2011). Immunodeficiency due to defects in store-operated calcium entry. Ann N Y Acad Sci 1238: 74-90.
30. FESKE S, SKOLNIK EY and PRAKRIYA M (2012). Ion channels and transporters in lymphocyte function and immunity. Nat Rev Immunol 12: 532-547.
31. Fuchs S, Rensing-Ehl A, SPECKMANN C, BENGSCH B, SCHMITT-GRAEFF A, BONDZIO I, MAUL-PAVICIC A, BASS T, VRAETZ T, STRAHM B, ANKERMANN T, BENSON M, CALIEBE A, FOLSTER-HOLST R, KAISER P, THIMME R, SCHAMEL WW, SCHWARZ K, FESKE S and EHL S (2012). Antiviral and regulatory T cell immunity in a patient with stromal interaction molecule 1 deficiency. J Immunol 188: 1523-1533.
32. Gallo EM, Cante-Barrett K and Crabtree GR (2006). Lymphocyte calcium signaling from membrane to nucleus. Nat Immunol 7: 25-32.
33. GARAUD S, MORVAA, LEMOINE S, HILLION S, BORDRON A, PERS JO, BERTHOU C, MAGEED RA, RENAUDINEAU Y and YOUINOU P (2011). CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 186: 4835-4844.
34. GARY-GOUY H, BRUHNS P, SCHMITT C, DALLOUL A, DAERON M and BISMUTH G (2000). The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling. J Biol Chem 275: 548-556.
35. GARY-GOUY H, HARRIAGUE J, BISMUTH G, PLATZER C, SCHMITT C and DALLOUL AH (2002). Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 100: 4537-4543.
36. GARY-GOUY H, HARRIAGUE J, DALLOUL A, DONNADIEU E and BISMUTH G (2002). CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif. J Immunol 168: 232-239.
37. GARY-GOUY H, SAINZ-PEREZ A, MARTEAU JB, MARFAING-KOKA A, DELIC J, MERLE-BERAL H, GALANAUD P and DALLOUL A(2007). Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol 179: 4335-4344.
38. GAULD SB, BENSCHOP RJ, MERRELL KT and CAMBIER JC (2005). Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 6: 1160-1167.
39. GAULD SB, MERRELL KT and CAMBIER JC (2006). Silencing of autoreactive B cells by anergy: a fresh perspective. Curr Opin Immunol 18: 292-297.
40. GHIA P, GUIDA G, STELLA S, GOTTARDI D, GEUNA M, STROLA G, SCIELZO C and CALIGARIS-CAPPIO F (2003). The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101: 1262-1269.
41. GOBESSI S, LAURENTI L, LONGO PG, CARSETTI L, BERNO V, SICA S, LEONE G and EFREMOV DG (2009). Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 23: 686-697.
42. GREENBERG EF, LAVIK AR and DISTELHORST CW (2014). Bcl-2 regulation of the inositol 1,4,5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: potential new target for cancer treatment. Biochim Biophys Acta 1843: 2205-2210.
43. HAYAKAWA K, SHINTON SA, ASANO M and HARDY RR (2000). B-1 cell definition. Curr Top Microbiol Immunol 252: 15-22.
44. HEALY JI, DOLMETSCH RE, TIMMERMAN LA, CYSTER JG, THOMAS ML, Crab-Tree GR, LEWIS RS and GOODNOW CC (1997). Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 6: 419-428.
45. HILL RJ, LOU Y and TAN SL (2013). B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities. Int Rev Immunol 32: 377-396.
46. HIPPEN KL, TZE LE and BEHRENS TW (2000). CD5 maintains tolerance in anergic B cells. J Exp Med 191: 883-890.
47. HIVROZ C, GENY B, BROUET JC and GRILLOT-COURVALIN C (1990). Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C. J Immunol 144: 2351-2358.
48. 2+ mobilization and cell proliferation. Eur J Immunol 18: 1811-1817.
49. HOEK KL, ANTONY P, LOWE J, SHINNERS N, SARMAH B, WENTE SR, WANG D, GERSTEIN RM and KHAN WN (2006). Transitional B cell fate is associated with developmental stage-specific regulation of diacylglycerol and calcium signaling upon B cell receptor engagement. J Immunol 177: 5405-5413.
50. JONES JA and BYRD JC (2014). How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 123: 1455-1460.
51. JUN JE and GOODNOW CC (2003). Scaffolding of antigen receptors for immunogenic versus tolerogenic signaling. Nat Immunol 4: 1057-1064.
52. KANE LP, LIN J and WEISS A (2000). Signal transduction by the TCR for antigen. Curr Opin Immunol 12: 242-249.
53. KUROSAKI T, SHINOHARA H and BABA Y (2010). B cell signaling and fate decision. Annu Rev Immunol 28: 21-55.
54. 2+ fluxes. Proc Natl Acad Sci USA 91: 6569-6573.
55. LANHAM S, HAMBLIN T, OSCIER D, IBBOTSON R, STEVENSON F and PACK-HAM G (2003). Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101: 1087-1093.
56. LANKESTER AC, SCHIJNDEL GM, PAKKER NG, VAN OERS RH and VAN LIER RA (1996). Antigen receptor function in chronic lymphocytic leukemia B cells. Leuk Lymphoma 24(1-2): 27-33.
57. LANKESTER AC, Van Schijndel GM, ROOD PM, VERHOEVEN AJ and VAN LIER RA (1994). B cell antigen receptor cross-linking induces tyrosine phosphorylation and membrane translocation of a multimeric Shc complex that is augmented by CD19 co-ligation. Eur J Immunol 24: 2818-2825.
58. LANKESTER AC, VAN SCHIJNDEL GM, VAN DER SCHOOT CE, VAN OERS MH, VAN NOESEL CJ and VAN LIER RA (1995). Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood 86: 1090-1097.
59. LE ROY C, DEGLESNE PA, CHEVALLIER N, BEITAR T, ECLACHE V, QUETTIER M, BOUBAYA M, LETESTU R, LEVY V, Ajchenbaum-Cymbalista F and Varin-Blank N (2012). The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia. Blood 120: 356-365.
60. LONGO PG, LAURENTI L, GOBESSI S, SICA S, LEONE G and EFREMOV DG (2008). The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111: 846-855.
61. MACIAN F, Garcia-Cozar F, IM SH, HORTON HF, BYRNE MC and RAO A (2002). Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109: 719-731.
62. MATSUMOTO M, FUJII Y, BABA A, HIKIDA M, KUROSAKI T and BABA Y (2011). The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity 34: 703-714.
63. MERRELL KT, BENSCHOP RJ, GAULD SB, AVISZUS K, Decote-Ricardo D, WYSOCKI LJ and CAMBIER JC (2006). Identification of anergic B cells within a wild-type repertoire. Immunity 25: 953-962.
64. MICHEL F, Merle-Beral H, LEGAC E, MICHEL A, DEBRE P and BISMUTH G (1993). Defective calcium response in B-chronic lymphocytic leukemia cells. Alteration of early protein tyrosine phosphorylation and of the mechanism responsible for cell calcium influx. J Immunol 150: 3624-3633.
65. MOCKRIDGE CI, POTTER KN, WHEATLEY I, NEVILLE LA, PACKHAM G and STEVENSON FK (2007). Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 109: 4424-4431.
66. MUZIO M, APOLLONIO B, SCIELZO C, FRENQUELLI M, VANDONI I, BOUSSIOTIS V, CALIGARIS-CAPPIO F and GHIA P (2008). Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 112: 188-195.
67. NEDELLEC S, RENAUDINEAU Y, BORDRON A, BERTHOU C, PORAKISHVILI N, LYDYARD PM, PERS JO and YOUINOU P (2005). B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. J Immunol 174: 3749-3756.
68. NIIRO H and CLARK EA (2002). Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2: 945-956.
69. OH-HORA M, YAMASHITA M, HOGAN PG, SHARMA S, LAMPERTI E, CHUNG W, PRAKRIYA M, FESKE S and RAO A (2008). Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nat Immunol 9: 432-443.
70. OKADA T, MAEDA A, IWAMATSU A, GOTOH K and KUROSAKI T (2000). BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 13: 817-827.
71. OKKENHAUG K and VANHAESEBROECK B (2003). PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3: 317-330.
72. PACKHAM G, KRYSOV S, ALLEN A, SAVELYEVA N, STEELE AJ, FORCONI F and STEVENSON FK (2014). The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica 99: 1138-1148.
73. PAO LI, LAM KP, HENDERSON JM, KUTOK JL, ALIMZHANOV M, NITSCHKE L, THOMAS ML, NEEL BG and RAJEWSKY K (2007). B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27: 35-48.
74. PEREZ-CHACON G, VARGAS JA, JORDA J, MORADO M, ROSADO S, MARTIN DONAIRE T, LOSADA-FERNANDEZ I, REBOLLEDA N and PEREZ-ACIEGO P (2007). CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. Leuk Res 31: 183-193.
75. PERS JO, BERTHOU C, PORAKISHVILI N, BURDJANADZE M, LE CALVEZ G, ABGRALL JF, LYDYARD PM, YOUINOU P and JAMIN C (2002). CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. Leukemia 16: 44-52.
76. PERS JO, JAMIN C, LE CORRE R, LYDYARD PM and YOUINOU P (1998). Ligation of CD5 on resting B cells, but not on resting T cells, results in apoptosis. Eur J Immunol 28: 4170-4176.
77. PETLICKOVSKI A, LAURENTI L, LI X, MARIETTI S, CHIUSOLO P, SICA S, LEONE G and EFREMOV DG (2005). Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 105: 4820-4827.
78. PICARD C, MCCARL CA, PAPOLOS A, KHALIL S, LUTHY K, HIVROZ C, LEDEIST F, RIEUX-LAUCAT F, RECHAVI G, RAO A, FISCHER A and FESKE S (2009). STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. N Engl J Med 360: 1971-1980.
79. PINTON P, FERRARI D, MAGALHAES P, Schulze Osthoff K, DI VIRGILIO F, POZZAN T and RIZZUTO R (2000). Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. J Cell Biol 148: 857-862.
80. POTTER KN, MOCKRIDGE CI, NEVILLE L, WHEATLEY I, SCHENK M, ORCHARD J, DUNCOMBE AS, PACKHAM G and STEVENSON FK (2006). Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 12: 1672-1679.
81. PRAKRIYA M (2013). Store-operated Orai channels: structure and function. Curr Top Membr 71: 1-32.
82. PUTNEY JW (2009). Capacitative calcium entry: from concept to molecules. Immunol Rev 231: 10-22.
83. PUTNEY JW, Jr. (2005). Capacitative calcium entry: sensing the calcium stores. J Cell Biol 169: 381-382.
84. QUACH TD, Manjarrez-Orduno N, ADLOWITZ DG, SILVER L, YANG H, WEI C, MILNER EC and SANZ I (2011). Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. J Immunol 186: 4640-4648.
85. RENAUDINEAU Y, NEDELLEC S, BERTHOU C, LYDYARD PM, YOUINOU P and PERS JO (2005). Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells. Leukemia 19: 223-229.
86. RINGSHAUSEN I, SCHNELLER F, BOGNER C, HIPP S, DUYSTER J, PESCHEL C and DECKER T (2002). Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 100: 3741-3748.
87. SANCHEZ BEATO M, Sanchez Aguilera A and PIRIS MA (2003). Cell cycle deregulation in B-cell lymphomas. Blood 101: 1220-1235.
88. SCARFO L and GHIA P (2013). Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett 155: 36-39.
89. SCHARENBERG AM and KINET JP (1998). PtdIns-3,4,5-P3: a regulatory nexus between tyrosine kinases and sustained calcium signals. Cell 94: 5-8.
90. SCHUH K, AVOTS A, TONY HP, SERFLING E and KNEITZ C (1996). Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk Lymphoma 23: 583-592.
91. SEDA V and MRAZ M (2015). B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 94: 193-205.
92. Semichon M, Merle Beral H, LANG V and BISMUTH G (1997). Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia 11: 1921-1928.
93. SHAW PJ and FESKE S (2012). Physiological and pathophysiological functions of SOCE in the immune system. Front Biosci (Elite Ed) 4: 2253-2268.
94. SHAW PJ and FESKE S (2012). Regulation of lymphocyte function by ORAI and STIM proteins in infection and autoimmunity. J Physiol 590(Pt 17): 4157-4167.
95. SINDHAVA VJ and BONDADA S (2012). Multiple regulatory mechanisms control B-1 B cell activation. Front Immunol 3: 372.
96. SOBOLOFF J, ROTHBERG BS, MADESH M and GILL DL (2012). STIM proteins: dynamic calcium signal transducers. Nat Rev Mol Cell Biol 13: 549-565.
97. SONG Z, LU P, FURMAN RR, LEONARD JP, MARTIN P, TYRELL L, LEE FY, KNOWLES DM, COLEMAN M and WANG YL (2010). Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res 16: 587-599.
98. STEVENSON FK, KRYSOV S, DAVIES AJ, STEELE AJ and PACKHAM G (2011). B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118: 4313-4320.
99. STEWART TA, YAPA KT and MONTEITH GR (2015). Altered calcium signaling in cancer cells. Biochim Biophys Acta. 1848: 2502-2511.
100. SU I and TARAKHOVSKY A (2000). B-1 cells: orthodox or conformist? Curr Opin Immunol 12: 191-194.
101. WONG SC, CHEW WK, TAN JE, MELENDEZ AJ, FRANCIS F and LAM KP (2002). Peritoneal CD5+ B-1 cells have signaling properties similar to tolerant B cells. J Biol Chem 277: 30707-30715.
102. YARKONI Y, GETAHUN A and CAMBIER JC (2010). Molecular underpinning of B-cell anergy. Immunol Rev 237: 249-263.
103. ZHANG S and KIPPS TJ (2014). The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol 9: 103-118.
104. ZUPO S, ISNARDI L, MEGNA M, MASSARA R, MALAVASI F, DONO M, COSULICH E and FERRARINI M (1996). CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 88: 1365-1374.
105. ZUPO S, MASSARA R, DONO M, ROSSI E, MALAVASI F, COSULICH ME and FERRARINI M (2000). Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 95: 1199-1206.